Lixte Biotechnology Holdings (LIXT) Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LIXT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.28 |
| 52 Week High | US$6.26 |
| 52 Week Low | US$0.64 |
| Beta | 0.50 |
| 1 Month Change | -15.42% |
| 3 Month Change | 14.75% |
| 1 Year Change | 105.77% |
| 3 Year Change | -10.83% |
| 5 Year Change | -92.87% |
| Change since IPO | -90.49% |
Recent News & Updates
Recent updates
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 08
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
May 05Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Jan 20We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
Jul 20Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 25Shareholder Returns
| LIXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.5% | -0.8% | 2.0% |
| 1Y | 105.8% | 2.9% | 18.7% |
Return vs Industry: LIXT exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: LIXT exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| LIXT volatility | |
|---|---|
| LIXT Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIXT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LIXT's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2 | Geordan Pursglove | lixte.com |
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| LIXT fundamental statistics | |
|---|---|
| Market cap | US$18.93m |
| Earnings (TTM) | -US$3.09m |
| Revenue (TTM) | n/a |
Is LIXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIXT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.09m |
| Earnings | -US$3.09m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LIXT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 22:26 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lixte Biotechnology Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.